Our specialists have each treated more than 5,000 multiple myeloma patients over two decades. The Multiple Myeloma Program at Holden Comprehensive Cancer Center, Iowa's only NCI-designated Comprehensive Cancer Center, is known for its tandem autologous transplant treatment, an approach offered at very few medical centers around the country.
Research demonstrates that the median survival rate with this treatment process is 10 years or more and that 80% of newly diagnosed myeloma patients will achieve complete remission. No other treatment method for multiple myeloma has proven to be as effective in research studies.
Patients of Holden Cancer Center benefit from a team-based approach that puts each patient at the center. At Holden, experts in specific cancer types—including a genetic counselor certified and specializing in cancer genetic counseling—is part of this team.
Holden patients also benefit from medical advances that take into account an individual’s tumor, genes, environment, and lifestyle to diagnose and treat their specific types of cancer. Known as personalized, or precision medicine, this highly specialized approach is part of Holden’s commitment to providing life-changing medical treatments and care. Multiple myeloma patients are seen in the Cancer Clinic, operated by Holden Comprehensive Cancer Center and located at Elevator M, Level 1 in the Pomerantz Pavilion of University of Iowa Hospitals and Clinics.
This spacious facility, which opened in December 2011, was designed by patients with patients in mind. The new space facilitates the team approach that has long been a hallmark of Holden Comprehensive Cancer Center in care for our patients.
The following is a list of myeloma clinical trials at this center.
View all active clinical trials around the US.
The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.
The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.
The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.
The following is a listing of clinical trials for patients with Smoldering Myeloma.
The following is a listing of clinical trials for patients with Monoclonal Gammopathy of Undetermined Significance (MGUS).
SparkCures is working closely with Holden Comprehensive Cancer Center to provide the most up-to-date information on their myeloma program, specialists and clinical trials. Use the buttons above to claim this as your Home Center or add it to your List of Favorites.
Learn more about how we work with myeloma centers